MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Total Liabilities 2011-2026 | NRC
Annual Total Liabilities National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 M | 101 M | 73.5 M | 58.4 M | 72.2 M | 69.1 M | 77.8 M | 88.9 M | 37.3 M | 37.8 M | 54.9 M | 41.8 M | 39.2 M | 43.3 M | 45.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 37.3 M | 64.1 M |
Quarterly Total Liabilities National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 M | 120 M | 106 M | 101 M | 97.2 M | 78.9 M | - | 73.5 M | 62.3 M | 55.9 M | 59.6 M | 58.4 M | 67.2 M | - | 71.7 M | 72.2 M | 73.1 M | 75.5 M | 73.6 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 77.8 M | 77.8 M | 77.8 M | 77.8 M | 88.9 M | 88.9 M | 88.9 M | 88.9 M | 37.3 M | 37.3 M | 37.3 M | 37.3 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 41.8 M | 41.8 M | 41.8 M | 41.8 M | 39.3 M | 39.3 M | 39.3 M | 39.2 M | 43.3 M | 43.3 M | 43.3 M | 43.3 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 37.3 M | 61.5 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 14.0 | 2.56 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
455 M | $ 8.91 | 0.51 % | $ 594 M | USA |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 25.85 | 0.08 % | $ 718 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
3.59 B | $ 67.92 | 2.38 % | $ 26.5 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 157.08 | 3.45 % | $ 7.79 B | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 17.51 | 1.07 % | $ 933 M | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | $ 103.81 | -0.04 % | $ 19.6 B | USA |
 |
Guardant Health
GH
|
2.11 B | $ 87.36 | 0.2 % | $ 11 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 15.45 | 3.34 % | $ 467 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
76.4 M | $ 17.14 | -0.87 % | $ 2.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 100.87 | 3.33 % | $ 8.32 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 2.86 | 0.7 % | $ 92.8 K | USA |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 170.64 | 3.54 % | $ 29.3 B | USA |
 |
Danaher Corporation
DHR
|
31.8 B | $ 196.09 | 2.46 % | $ 140 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 120.51 | 1.03 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 199.89 | 0.48 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
5.32 B | $ 114.44 | 2.33 % | $ 34.8 B | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.11 | -0.45 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 8.74 | 3.8 % | $ 248 M | Israel |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.31 | 2.2 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 78.85 | 0.45 % | $ 5.32 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.39 | 1.84 % | $ 417 M | USA |
 |
Co-Diagnostics
CODX
|
9.31 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 461.07 | 1.64 % | $ 13.3 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 224.83 | 2.14 % | $ 25.2 B |  Schweiz |
 |
Celcuity
CELC
|
130 M | $ 113.19 | -1.49 % | $ 4.47 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 8.4 | 2.0 % | $ 1.08 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
689 M | $ 201.85 | 2.11 % | $ 19.9 B | USA |
 |
OPKO Health
OPK
|
835 M | $ 1.2 | 0.84 % | $ 833 M | USA |